Rajiv Anant Patel
Private Equity Investor bij Farallon Capital Management (Private Equity)
Profiel
Rajiv Anant Patel is a Partner at Farallon Capital Management (Private Equity) since 1997.
He was a Director at Flowonix Medical, Inc. and an Investment Banker at Donaldson, Lufkin & Jenrette Securities Corp.
He was also a Non-Executive Director at Nexvet Biopharma Plc from 2015 to 2017 and an Independent Non-Executive Director at Nexvet Australia Pty Ltd.
Mr. Patel holds an undergraduate degree from Cornell University and an MBA from Stanford Graduate School of Business.
Actieve functies van Rajiv Anant Patel
Bedrijven | Functie | Begin |
---|---|---|
Farallon Capital Management (Private Equity)
Farallon Capital Management (Private Equity) Investment ManagersFinance Farallon Capital Management (Private Equity) (Farallon Capital) is a private equity firm, a subsidiary of Farallon Capital Management LLC founded in 1986 by Thomas Fahr Steyer. The firm is headquartered in San Francisco, California. | Private Equity Investor | 01-01-1997 |
Eerdere bekende functies van Rajiv Anant Patel
Bedrijven | Functie | Einde |
---|---|---|
NEXVET BIOPHARMA PUBLIC LIMITED CO | Directeur/Bestuurslid | 31-07-2017 |
Donaldson, Lufkin & Jenrette Securities Corp. | Corporate Officer/Principal | - |
Flowonix Medical, Inc.
Flowonix Medical, Inc. Medical SpecialtiesHealth Technology Flowonix Medical, Inc. designs and develops proprietary implantable pumps. It provides implantable intrathecal pumps to help manage chronic pain for cancer patients and patients with back pain. The company was founded in 2005 and is headquartered in Mt. Olive, NJ. | Directeur/Bestuurslid | - |
Nexvet Australia Pty Ltd.
Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Directeur/Bestuurslid | - |
Opleiding van Rajiv Anant Patel
Cornell University | Undergraduate Degree |
Stanford Graduate School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
Donaldson, Lufkin & Jenrette Securities Corp. | Finance |
Farallon Capital Management (Private Equity)
Farallon Capital Management (Private Equity) Investment ManagersFinance Farallon Capital Management (Private Equity) (Farallon Capital) is a private equity firm, a subsidiary of Farallon Capital Management LLC founded in 1986 by Thomas Fahr Steyer. The firm is headquartered in San Francisco, California. | Finance |
Nexvet Biopharma Plc
Nexvet Biopharma Plc Pharmaceuticals: MajorHealth Technology Nexvet Biopharma Plc engaged in the provision of integrated biopharmaceutical business. It focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. The company was founded in September 2014 and was headquartered in Dublin, Ireland. | Health Technology |
Nexvet Australia Pty Ltd.
Nexvet Australia Pty Ltd. Pharmaceuticals: MajorHealth Technology Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia. | Health Technology |
Flowonix Medical, Inc.
Flowonix Medical, Inc. Medical SpecialtiesHealth Technology Flowonix Medical, Inc. designs and develops proprietary implantable pumps. It provides implantable intrathecal pumps to help manage chronic pain for cancer patients and patients with back pain. The company was founded in 2005 and is headquartered in Mt. Olive, NJ. | Health Technology |